{ "source": "Nasdaq Nordic Company News", "fetcher_build": "2026-08-03-nasdaq-cns-annual-period-v5.0.10", "status": "retrieved", "company": "Vicore Pharma Holding", "reports": [ { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-03-nasdaq-cns-annual-period-v5.0.10", "retrieved_at": "2026-08-04T19:45:46Z", "company": "Vicore Pharma Holding AB", "title": "Delårsrapport januari - mars 2026", "category": "Interimsrapport", "date": "2026-05-06", "language": "sv", "report_type": "interim-report", "fiscal_year": 2026, "quarter": "q1", "period": "2026-q1", "report_key": "2026:q1", "release_url": "https://view.news.eu.nasdaq.com/view?id=b00c6b9419fef5bc28396a5eea3441408&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2026-q1\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2026-q1\\release.txt", "attachments": [ { "label": "Delarsrapport Q1 2026.pdf", "url": "https://attachment.news.eu.nasdaq.com/a17a9a42943519ac9b9499fe483dd8fb0", "final_url": "https://attachment.news.eu.nasdaq.com/a17a9a42943519ac9b9499fe483dd8fb0", "filename": "Delarsrapport_Q1_2026.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2026-q1\\Delarsrapport_Q1_2026.pdf", "content_type": "application/pdf", "size": 2450762, "sha256": "09147e95128f9573312939d88e4cd55ef0f44869b0d6c2e67669fdb18de078a2", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2026-q1\\Delarsrapport_Q1_2026.pdf", "filename": "Delarsrapport_Q1_2026.pdf", "extension": ".pdf", "size": 2450762, "sha256": "09147e95128f9573312939d88e4cd55ef0f44869b0d6c2e67669fdb18de078a2", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2026-q1\\extracted\\Delarsrapport_Q1_2026\\Delarsrapport_Q1_2026.txt", "text_chars": 43334, "metadata": { "page_count": 21, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2026-q1\\extracted\\Delarsrapport_Q1_2026\\Delarsrapport_Q1_2026.extraction.json" } } ], "announcement_id": "1439989", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-03-nasdaq-cns-annual-period-v5.0.10", "retrieved_at": "2026-08-04T19:45:55Z", "company": "Vicore Pharma Holding AB", "title": "Vicore offentliggör årsredovisning för 2025", "category": "Bokslut och Verksamhetsberättelse", "date": "2026-03-26", "language": "sv", "report_type": "annual-report", "fiscal_year": 2025, "quarter": "annual", "period": "2025-annual", "report_key": "2025:annual", "release_url": "https://view.news.eu.nasdaq.com/view?id=b600d68604b5fc3eac062c3954b408421&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2025-annual\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2025-annual\\release.txt", "attachments": [ { "label": "Vicore Arsredovisning 2025.pdf", "url": "https://attachment.news.eu.nasdaq.com/ac8734d7900ed05a77157d57e58b8b371", "final_url": "https://attachment.news.eu.nasdaq.com/ac8734d7900ed05a77157d57e58b8b371", "filename": "Vicore_Arsredovisning_2025.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2025-annual\\Vicore_Arsredovisning_2025.pdf", "content_type": "application/pdf", "size": 4845462, "sha256": "cf21b11fe94cda4920e011e4e767df699b1349e5f5e2c869b360c68369924dd6", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2025-annual\\Vicore_Arsredovisning_2025.pdf", "filename": "Vicore_Arsredovisning_2025.pdf", "extension": ".pdf", "size": 4845462, "sha256": "cf21b11fe94cda4920e011e4e767df699b1349e5f5e2c869b360c68369924dd6", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2025-annual\\extracted\\Vicore_Arsredovisning_2025\\Vicore_Arsredovisning_2025.txt", "text_chars": 264632, "metadata": { "page_count": 74, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2025-annual\\extracted\\Vicore_Arsredovisning_2025\\Vicore_Arsredovisning_2025.extraction.json" } } ], "announcement_id": "1429038", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-03-nasdaq-cns-annual-period-v5.0.10", "retrieved_at": "2026-08-04T19:45:59Z", "company": "Vicore Pharma Holding AB", "title": "Bokslutskommuniké 2025", "category": "Bokslutskommuniké", "date": "2026-02-27", "language": "sv", "report_type": "year-end-report", "fiscal_year": 2025, "quarter": "q4", "period": "2025-q4", "report_key": "2025:q4", "release_url": "https://view.news.eu.nasdaq.com/view?id=b72784e8b83c8522ce08632a00a87ef39&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2025-q4\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2025-q4\\release.txt", "attachments": [ { "label": "Bokslutskommunike 2025.pdf", "url": "https://attachment.news.eu.nasdaq.com/afd2d355616d2dcdf9003f1247ed96a80", "final_url": "https://attachment.news.eu.nasdaq.com/afd2d355616d2dcdf9003f1247ed96a80", "filename": "Bokslutskommunike_2025.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2025-q4\\Bokslutskommunike_2025.pdf", "content_type": "application/pdf", "size": 15534040, "sha256": "7e4a990abee0deb5b338104e95f47947087f925b89faba7d499c506c37cc4b57", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2025-q4\\Bokslutskommunike_2025.pdf", "filename": "Bokslutskommunike_2025.pdf", "extension": ".pdf", "size": 15534040, "sha256": "7e4a990abee0deb5b338104e95f47947087f925b89faba7d499c506c37cc4b57", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2025-q4\\extracted\\Bokslutskommunike_2025\\Bokslutskommunike_2025.txt", "text_chars": 48919, "metadata": { "page_count": 21, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2025-q4\\extracted\\Bokslutskommunike_2025\\Bokslutskommunike_2025.extraction.json" } } ], "announcement_id": "1423092", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-03-nasdaq-cns-annual-period-v5.0.10", "retrieved_at": "2026-08-04T19:46:02Z", "company": "Vicore Pharma Holding AB", "title": "Delårsrapport juli-september 2025", "category": "Interimsrapport", "date": "2025-11-05", "language": "sv", "report_type": "interim-report", "fiscal_year": 2025, "quarter": "q3", "period": "2025-q3", "report_key": "2025:q3", "release_url": "https://view.news.eu.nasdaq.com/view?id=b7db3aa72a81418db70ff496c131bfcc0&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2025-q3\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2025-q3\\release.txt", "attachments": [ { "label": "Delarsrapport Q3 2025.pdf", "url": "https://attachment.news.eu.nasdaq.com/a29e802aad5879985f414115f16438495", "final_url": "https://attachment.news.eu.nasdaq.com/a29e802aad5879985f414115f16438495", "filename": "Delarsrapport_Q3_2025.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2025-q3\\Delarsrapport_Q3_2025.pdf", "content_type": "application/pdf", "size": 2335913, "sha256": "0e5199bb265cc9be60565f6340f00d5a45b86ab1b999286b68a23102291bd697", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2025-q3\\Delarsrapport_Q3_2025.pdf", "filename": "Delarsrapport_Q3_2025.pdf", "extension": ".pdf", "size": 2335913, "sha256": "0e5199bb265cc9be60565f6340f00d5a45b86ab1b999286b68a23102291bd697", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2025-q3\\extracted\\Delarsrapport_Q3_2025\\Delarsrapport_Q3_2025.txt", "text_chars": 51972, "metadata": { "page_count": 22, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2025-q3\\extracted\\Delarsrapport_Q3_2025\\Delarsrapport_Q3_2025.extraction.json" } } ], "announcement_id": "1398735", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-03-nasdaq-cns-annual-period-v5.0.10", "retrieved_at": "2026-08-04T19:46:07Z", "company": "Vicore Pharma Holding AB", "title": "Delårsrapport april-juni 2025", "category": "Halvårsrapport", "date": "2025-08-22", "language": "sv", "report_type": "interim-report", "fiscal_year": 2025, "quarter": "q2", "period": "2025-q2", "report_key": "2025:q2", "release_url": "https://view.news.eu.nasdaq.com/view?id=b97f6d13a90c2672b76c146ae640a80cb&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2025-q2\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2025-q2\\release.txt", "attachments": [ { "label": "Delarsrapport Q2 2025.pdf", "url": "https://attachment.news.eu.nasdaq.com/a601e14263c6a6dcc72f09a601e5b2ca5", "final_url": "https://attachment.news.eu.nasdaq.com/a601e14263c6a6dcc72f09a601e5b2ca5", "filename": "Delarsrapport_Q2_2025.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2025-q2\\Delarsrapport_Q2_2025.pdf", "content_type": "application/pdf", "size": 2313060, "sha256": "4f5e331a70cc9772f9dd39e6df020504fac3d16ca61251bf208d4a16873d736a", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2025-q2\\Delarsrapport_Q2_2025.pdf", "filename": "Delarsrapport_Q2_2025.pdf", "extension": ".pdf", "size": 2313060, "sha256": "4f5e331a70cc9772f9dd39e6df020504fac3d16ca61251bf208d4a16873d736a", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2025-q2\\extracted\\Delarsrapport_Q2_2025\\Delarsrapport_Q2_2025.txt", "text_chars": 46643, "metadata": { "page_count": 21, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2025-q2\\extracted\\Delarsrapport_Q2_2025\\Delarsrapport_Q2_2025.extraction.json" } } ], "announcement_id": "1384707", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-03-nasdaq-cns-annual-period-v5.0.10", "retrieved_at": "2026-08-04T19:46:13Z", "company": "Vicore Pharma Holding AB", "title": "Delårsrapport januari-mars 2025", "category": "Interimsrapport", "date": "2025-05-06", "language": "sv", "report_type": "interim-report", "fiscal_year": 2025, "quarter": "q1", "period": "2025-q1", "report_key": "2025:q1", "release_url": "https://view.news.eu.nasdaq.com/view?id=b3054c17c4a86c0f5b08a02f0e9590b1e&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2025-q1\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2025-q1\\release.txt", "attachments": [ { "label": "Delarsrapport 1 Jan 31 Mar 2025.pdf", "url": "https://attachment.news.eu.nasdaq.com/ad1ca81c15c657972c0cbda55b9a6cf97", "final_url": "https://attachment.news.eu.nasdaq.com/ad1ca81c15c657972c0cbda55b9a6cf97", "filename": "Delarsrapport_1_Jan_31_Mar_2025.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2025-q1\\Delarsrapport_1_Jan_31_Mar_2025.pdf", "content_type": "application/pdf", "size": 16074129, "sha256": "161203666816ea945e02334a7230bae78a4e1ea2e6b137545068c9a8eaa7c3c3", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2025-q1\\Delarsrapport_1_Jan_31_Mar_2025.pdf", "filename": "Delarsrapport_1_Jan_31_Mar_2025.pdf", "extension": ".pdf", "size": 16074129, "sha256": "161203666816ea945e02334a7230bae78a4e1ea2e6b137545068c9a8eaa7c3c3", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2025-q1\\extracted\\Delarsrapport_1_Jan_31_Mar_2025\\Delarsrapport_1_Jan_31_Mar_2025.txt", "text_chars": 45176, "metadata": { "page_count": 21, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2025-q1\\extracted\\Delarsrapport_1_Jan_31_Mar_2025\\Delarsrapport_1_Jan_31_Mar_2025.extraction.json" } } ], "announcement_id": "1360921", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-03-nasdaq-cns-annual-period-v5.0.10", "retrieved_at": "2026-08-04T19:46:25Z", "company": "Vicore Pharma Holding AB", "title": "Vicore offentliggör årsredovisning för 2024", "category": "Bokslut och Verksamhetsberättelse", "date": "2025-03-26", "language": "sv", "report_type": "annual-report", "fiscal_year": 2024, "quarter": "annual", "period": "2024-annual", "report_key": "2024:annual", "release_url": "https://view.news.eu.nasdaq.com/view?id=bdd4d68888e865bc214adcdd4677b1d08&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2024-annual\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2024-annual\\release.txt", "attachments": [ { "label": "Vicore Arsredovisning 2024.pdf", "url": "https://attachment.news.eu.nasdaq.com/a66794ceb802528c55ffb3b1ee8c7dc30", "final_url": "https://attachment.news.eu.nasdaq.com/a66794ceb802528c55ffb3b1ee8c7dc30", "filename": "Vicore_Arsredovisning_2024.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2024-annual\\Vicore_Arsredovisning_2024.pdf", "content_type": "application/pdf", "size": 26386274, "sha256": "e628a6484cb38d6916f50f4bc7eb4107854107a6b4209198279eeffc4e890f83", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2024-annual\\Vicore_Arsredovisning_2024.pdf", "filename": "Vicore_Arsredovisning_2024.pdf", "extension": ".pdf", "size": 26386274, "sha256": "e628a6484cb38d6916f50f4bc7eb4107854107a6b4209198279eeffc4e890f83", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2024-annual\\extracted\\Vicore_Arsredovisning_2024\\Vicore_Arsredovisning_2024.txt", "text_chars": 287791, "metadata": { "page_count": 76, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2024-annual\\extracted\\Vicore_Arsredovisning_2024\\Vicore_Arsredovisning_2024.extraction.json" } } ], "announcement_id": "1351212", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-03-nasdaq-cns-annual-period-v5.0.10", "retrieved_at": "2026-08-04T19:46:28Z", "company": "Vicore Pharma Holding AB", "title": "Bokslutskommuniké 2024", "category": "Bokslutskommuniké", "date": "2025-02-27", "language": "sv", "report_type": "year-end-report", "fiscal_year": 2024, "quarter": "q4", "period": "2024-q4", "report_key": "2024:q4", "release_url": "https://view.news.eu.nasdaq.com/view?id=b360b480bb9fc49e165fd522b72bf1b42&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2024-q4\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2024-q4\\release.txt", "attachments": [ { "label": "Bokslutskommunike 2024 SWE.pdf", "url": "https://attachment.news.eu.nasdaq.com/ae73c8303818455588695b9a0c1a06058", "final_url": "https://attachment.news.eu.nasdaq.com/ae73c8303818455588695b9a0c1a06058", "filename": "Bokslutskommunike_2024_SWE.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2024-q4\\Bokslutskommunike_2024_SWE.pdf", "content_type": "application/pdf", "size": 6760211, "sha256": "d4ea4a7ef8edb2a85eb7b43efde15f54c7399e3b60bc62edffc2942f1effadfd", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2024-q4\\Bokslutskommunike_2024_SWE.pdf", "filename": "Bokslutskommunike_2024_SWE.pdf", "extension": ".pdf", "size": 6760211, "sha256": "d4ea4a7ef8edb2a85eb7b43efde15f54c7399e3b60bc62edffc2942f1effadfd", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2024-q4\\extracted\\Bokslutskommunike_2024_SWE\\Bokslutskommunike_2024_SWE.txt", "text_chars": 49883, "metadata": { "page_count": 20, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2024-q4\\extracted\\Bokslutskommunike_2024_SWE\\Bokslutskommunike_2024_SWE.extraction.json" } } ], "announcement_id": "1345606", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-03-nasdaq-cns-annual-period-v5.0.10", "retrieved_at": "2026-08-04T19:46:34Z", "company": "Vicore Pharma Holding AB", "title": "Delårsrapport juli-september 2024", "category": "Interimsrapport", "date": "2024-11-05", "language": "sv", "report_type": "interim-report", "fiscal_year": 2024, "quarter": "q3", "period": "2024-q3", "report_key": "2024:q3", "release_url": "https://view.news.eu.nasdaq.com/view?id=ba1091d4997b1ad6a448ff25af01915e0&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2024-q3\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2024-q3\\release.txt", "attachments": [ { "label": "Delarsrapport Q3 2024.pdf", "url": "https://attachment.news.eu.nasdaq.com/a5e2cc4eb1aa5dacb7918657cd4a93246", "final_url": "https://attachment.news.eu.nasdaq.com/a5e2cc4eb1aa5dacb7918657cd4a93246", "filename": "Delarsrapport_Q3_2024.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2024-q3\\Delarsrapport_Q3_2024.pdf", "content_type": "application/pdf", "size": 7851673, "sha256": "d71acb6909f6dc0064559b9d5eada617dc7a5aa63bb83175f56d6ad761982ba0", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2024-q3\\Delarsrapport_Q3_2024.pdf", "filename": "Delarsrapport_Q3_2024.pdf", "extension": ".pdf", "size": 7851673, "sha256": "d71acb6909f6dc0064559b9d5eada617dc7a5aa63bb83175f56d6ad761982ba0", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2024-q3\\extracted\\Delarsrapport_Q3_2024\\Delarsrapport_Q3_2024.txt", "text_chars": 50324, "metadata": { "page_count": 21, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2024-q3\\extracted\\Delarsrapport_Q3_2024\\Delarsrapport_Q3_2024.extraction.json" } } ], "announcement_id": "1325696", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-03-nasdaq-cns-annual-period-v5.0.10", "retrieved_at": "2026-08-04T19:46:39Z", "company": "Vicore Pharma Holding AB", "title": "Delårsrapport april-juni 2024", "category": "Halvårsrapport", "date": "2024-08-22", "language": "sv", "report_type": "interim-report", "fiscal_year": 2024, "quarter": "q2", "period": "2024-q2", "report_key": "2024:q2", "release_url": "https://view.news.eu.nasdaq.com/view?id=b8e0088e8cb4bbbc4bdd222a8d48f4385&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2024-q2\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2024-q2\\release.txt", "attachments": [ { "label": "Delarsrapport Q2 2024.pdf", "url": "https://attachment.news.eu.nasdaq.com/ac33a252ae1cac6377103173b7acabf2c", "final_url": "https://attachment.news.eu.nasdaq.com/ac33a252ae1cac6377103173b7acabf2c", "filename": "Delarsrapport_Q2_2024.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2024-q2\\Delarsrapport_Q2_2024.pdf", "content_type": "application/pdf", "size": 3972955, "sha256": "b1aba9ecf5644930cba10892b99fbd6453b3cb18fcd3bba129bfe31e5a67ade5", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2024-q2\\Delarsrapport_Q2_2024.pdf", "filename": "Delarsrapport_Q2_2024.pdf", "extension": ".pdf", "size": 3972955, "sha256": "b1aba9ecf5644930cba10892b99fbd6453b3cb18fcd3bba129bfe31e5a67ade5", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2024-q2\\extracted\\Delarsrapport_Q2_2024\\Delarsrapport_Q2_2024.txt", "text_chars": 44660, "metadata": { "page_count": 19, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2024-q2\\extracted\\Delarsrapport_Q2_2024\\Delarsrapport_Q2_2024.extraction.json" } } ], "announcement_id": "1312153", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-03-nasdaq-cns-annual-period-v5.0.10", "retrieved_at": "2026-08-04T19:46:46Z", "company": "Vicore Pharma Holding AB", "title": "Delårsrapport januari-mars 2024", "category": "Interimsrapport", "date": "2024-05-03", "language": "sv", "report_type": "interim-report", "fiscal_year": 2024, "quarter": "q1", "period": "2024-q1", "report_key": "2024:q1", "release_url": "https://view.news.eu.nasdaq.com/view?id=b07abb63329fd21adf8d4a9f2ba0e3bb6&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2024-q1\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2024-q1\\release.txt", "attachments": [ { "label": "Delarsrapport Q1 2024 FINAL.pdf", "url": "https://attachment.news.eu.nasdaq.com/aacba62192026d1de39a5f33b4daf9986", "final_url": "https://attachment.news.eu.nasdaq.com/aacba62192026d1de39a5f33b4daf9986", "filename": "Delarsrapport_Q1_2024_FINAL.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2024-q1\\Delarsrapport_Q1_2024_FINAL.pdf", "content_type": "application/pdf", "size": 7823447, "sha256": "4bb721d5cd96b117a2187fe95d2cbeaeb4ef1620ebcc885308a87e4feba34f5d", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2024-q1\\Delarsrapport_Q1_2024_FINAL.pdf", "filename": "Delarsrapport_Q1_2024_FINAL.pdf", "extension": ".pdf", "size": 7823447, "sha256": "4bb721d5cd96b117a2187fe95d2cbeaeb4ef1620ebcc885308a87e4feba34f5d", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2024-q1\\extracted\\Delarsrapport_Q1_2024_FINAL\\Delarsrapport_Q1_2024_FINAL.txt", "text_chars": 41479, "metadata": { "page_count": 19, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2024-q1\\extracted\\Delarsrapport_Q1_2024_FINAL\\Delarsrapport_Q1_2024_FINAL.extraction.json" } } ], "announcement_id": "1292972", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-03-nasdaq-cns-annual-period-v5.0.10", "retrieved_at": "2026-08-04T19:46:52Z", "company": "Vicore Pharma Holding AB", "title": "Vicore offentliggör årsredovisning för 2023", "category": "Bokslut och Verksamhetsberättelse", "date": "2024-03-27", "language": "sv", "report_type": "annual-report", "fiscal_year": 2023, "quarter": "annual", "period": "2023-annual", "report_key": "2023:annual", "release_url": "https://view.news.eu.nasdaq.com/view?id=bd7b3e65ea8ded43a8959cfcf5981d5eb&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2023-annual\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2023-annual\\release.txt", "attachments": [ { "label": "Vicore Arsredovisning 2023.pdf", "url": "https://attachment.news.eu.nasdaq.com/a2ae7c68718235fae332b816f53ab1738", "final_url": "https://attachment.news.eu.nasdaq.com/a2ae7c68718235fae332b816f53ab1738", "filename": "Vicore_Arsredovisning_2023.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2023-annual\\Vicore_Arsredovisning_2023.pdf", "content_type": "application/pdf", "size": 4751574, "sha256": "8cd42f435d0f31bff067af1f3f30fc1a7412f89d76ced868bea0929d79c6716a", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2023-annual\\Vicore_Arsredovisning_2023.pdf", "filename": "Vicore_Arsredovisning_2023.pdf", "extension": ".pdf", "size": 4751574, "sha256": "8cd42f435d0f31bff067af1f3f30fc1a7412f89d76ced868bea0929d79c6716a", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2023-annual\\extracted\\Vicore_Arsredovisning_2023\\Vicore_Arsredovisning_2023.txt", "text_chars": 269652, "metadata": { "page_count": 74, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2023-annual\\extracted\\Vicore_Arsredovisning_2023\\Vicore_Arsredovisning_2023.extraction.json" } } ], "announcement_id": "1284104", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-03-nasdaq-cns-annual-period-v5.0.10", "retrieved_at": "2026-08-04T19:46:55Z", "company": "Vicore Pharma Holding AB", "title": "Bokslutskommuniké 2023", "category": "Bokslutskommuniké", "date": "2024-02-28", "language": "sv", "report_type": "year-end-report", "fiscal_year": 2023, "quarter": "q4", "period": "2023-q4", "report_key": "2023:q4", "release_url": "https://view.news.eu.nasdaq.com/view?id=b5cb03fd0542c64e01c883b37cd1f5acd&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2023-q4\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2023-q4\\release.txt", "attachments": [ { "label": "Bokslutskommunike 2023.pdf", "url": "https://attachment.news.eu.nasdaq.com/ad4f6a640bbf90aa0f94b72149a909dbd", "final_url": "https://attachment.news.eu.nasdaq.com/ad4f6a640bbf90aa0f94b72149a909dbd", "filename": "Bokslutskommunike_2023.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2023-q4\\Bokslutskommunike_2023.pdf", "content_type": "application/pdf", "size": 7856625, "sha256": "f652188f84d1a7e121c4fd947d8c3929e298979d50634fa8ca98838242c02eab", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2023-q4\\Bokslutskommunike_2023.pdf", "filename": "Bokslutskommunike_2023.pdf", "extension": ".pdf", "size": 7856625, "sha256": "f652188f84d1a7e121c4fd947d8c3929e298979d50634fa8ca98838242c02eab", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2023-q4\\extracted\\Bokslutskommunike_2023\\Bokslutskommunike_2023.txt", "text_chars": 45516, "metadata": { "page_count": 19, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2023-q4\\extracted\\Bokslutskommunike_2023\\Bokslutskommunike_2023.extraction.json" } } ], "announcement_id": "1277831", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-03-nasdaq-cns-annual-period-v5.0.10", "retrieved_at": "2026-08-04T19:47:00Z", "company": "Vicore Pharma Holding AB", "title": "Delårsrapport juli-september 2023", "category": "Interimsrapport", "date": "2023-11-02", "language": "sv", "report_type": "interim-report", "fiscal_year": 2023, "quarter": "q3", "period": "2023-q3", "report_key": "2023:q3", "release_url": "https://view.news.eu.nasdaq.com/view?id=b2c54299bcf62d6367d586a5c4588c58f&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2023-q3\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2023-q3\\release.txt", "attachments": [ { "label": "Delarsrapport Q3 2023.pdf", "url": "https://attachment.news.eu.nasdaq.com/a0e437a99b9af6d9ca3735b061af97537", "final_url": "https://attachment.news.eu.nasdaq.com/a0e437a99b9af6d9ca3735b061af97537", "filename": "Delarsrapport_Q3_2023.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2023-q3\\Delarsrapport_Q3_2023.pdf", "content_type": "application/pdf", "size": 7865296, "sha256": "3344bafc5252080871c96ece9a38f5b51c9d7b3b10a360129f1a7bef78146d4d", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2023-q3\\Delarsrapport_Q3_2023.pdf", "filename": "Delarsrapport_Q3_2023.pdf", "extension": ".pdf", "size": 7865296, "sha256": "3344bafc5252080871c96ece9a38f5b51c9d7b3b10a360129f1a7bef78146d4d", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2023-q3\\extracted\\Delarsrapport_Q3_2023\\Delarsrapport_Q3_2023.txt", "text_chars": 43926, "metadata": { "page_count": 20, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2023-q3\\extracted\\Delarsrapport_Q3_2023\\Delarsrapport_Q3_2023.extraction.json" } } ], "announcement_id": "1256745", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-03-nasdaq-cns-annual-period-v5.0.10", "retrieved_at": "2026-08-04T19:47:05Z", "company": "Vicore Pharma Holding AB", "title": "Delårsrapport april-juni 2023", "category": "Halvårsrapport", "date": "2023-08-24", "language": "sv", "report_type": "interim-report", "fiscal_year": 2023, "quarter": "q2", "period": "2023-q2", "report_key": "2023:q2", "release_url": "https://view.news.eu.nasdaq.com/view?id=b9c1e213206b463347e49c17c1c83df25&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2023-q2\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2023-q2\\release.txt", "attachments": [ { "label": "Delarsrapport April Juni 2023.pdf", "url": "https://attachment.news.eu.nasdaq.com/ade8c9e5626a289c75d0d5612b408bc0b", "final_url": "https://attachment.news.eu.nasdaq.com/ade8c9e5626a289c75d0d5612b408bc0b", "filename": "Delarsrapport_April_Juni_2023.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2023-q2\\Delarsrapport_April_Juni_2023.pdf", "content_type": "application/pdf", "size": 6660882, "sha256": "fc851ed2d2aaaac8bab7199536d85cdbc693257f10bbf79d95a307b89d767da2", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2023-q2\\Delarsrapport_April_Juni_2023.pdf", "filename": "Delarsrapport_April_Juni_2023.pdf", "extension": ".pdf", "size": 6660882, "sha256": "fc851ed2d2aaaac8bab7199536d85cdbc693257f10bbf79d95a307b89d767da2", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2023-q2\\extracted\\Delarsrapport_April_Juni_2023\\Delarsrapport_April_Juni_2023.txt", "text_chars": 42123, "metadata": { "page_count": 19, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2023-q2\\extracted\\Delarsrapport_April_Juni_2023\\Delarsrapport_April_Juni_2023.extraction.json" } } ], "announcement_id": "1244174", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-03-nasdaq-cns-annual-period-v5.0.10", "retrieved_at": "2026-08-04T19:47:09Z", "company": "Vicore Pharma Holding AB", "title": "Rättelse: Delårsrapport januari-mars 2023", "category": "Interimsrapport", "date": "2023-05-04", "language": "sv", "report_type": "interim-report", "fiscal_year": 2023, "quarter": "q1", "period": "2023-q1", "report_key": "2023:q1", "release_url": "https://view.news.eu.nasdaq.com/view?id=b135579da42267f8c35aef4506d1d7e46&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2023-q1\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2023-q1\\release.txt", "attachments": [ { "label": "Delarsrapport Jan Mar 2023.pdf", "url": "https://attachment.news.eu.nasdaq.com/a4a08c7c7e1a6de7650f7cc53f699d9bf", "final_url": "https://attachment.news.eu.nasdaq.com/a4a08c7c7e1a6de7650f7cc53f699d9bf", "filename": "Delarsrapport_Jan_Mar_2023.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2023-q1\\Delarsrapport_Jan_Mar_2023.pdf", "content_type": "application/pdf", "size": 7261942, "sha256": "8e7ec395406e329278366eab28393e92de4ec1fbc55fc025a82ed1d7356fea5b", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2023-q1\\Delarsrapport_Jan_Mar_2023.pdf", "filename": "Delarsrapport_Jan_Mar_2023.pdf", "extension": ".pdf", "size": 7261942, "sha256": "8e7ec395406e329278366eab28393e92de4ec1fbc55fc025a82ed1d7356fea5b", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2023-q1\\extracted\\Delarsrapport_Jan_Mar_2023\\Delarsrapport_Jan_Mar_2023.txt", "text_chars": 39808, "metadata": { "page_count": 19, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\vicore-pharma-holding\\nasdaq-reports\\reports\\2023-q1\\extracted\\Delarsrapport_Jan_Mar_2023\\Delarsrapport_Jan_Mar_2023.extraction.json" } } ], "announcement_id": "1225430", "status": "retrieved" } ], "attempts": [ { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=Vicore+Pharma+Holding&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicMainMarkets&displayLanguage=sv&language=sv&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=0&dir=DESC", "status": 200, "scope": "NordicMainMarkets", "language": "sv", "start": 0, "pagination": "row-offset", "query_text": "Vicore Pharma Holding", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 100, "new_rows": 100, "total_count": null, "from_cache": false, "body_sha256": "f5afbe736db18585007664a06545ae4a107520c28170ca7c33a00b5d75cc72f0" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=Vicore+Pharma+Holding&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicMainMarkets&displayLanguage=sv&language=sv&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=100&dir=DESC", "status": 200, "scope": "NordicMainMarkets", "language": "sv", "start": 100, "pagination": "row-offset", "query_text": "Vicore Pharma Holding", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 100, "new_rows": 100, "total_count": null, "from_cache": false, "body_sha256": "18d02525e27e3e80b9f8c6fbcfb66fa118cf69a93fd27d1cd8aa4e79f0b38904" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=Vicore+Pharma+Holding&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicMainMarkets&displayLanguage=sv&language=sv&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=200&dir=DESC", "status": 200, "scope": "NordicMainMarkets", "language": "sv", "start": 200, "pagination": "row-offset", "query_text": "Vicore Pharma Holding", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 66, "new_rows": 66, "total_count": null, "from_cache": false, "body_sha256": "db7c8f89084e30faf6993f4f8fdd5d7843bb963acb3b20c1513979e7b9237eb1" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=Vicore+Pharma+Holding&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicMainMarkets&displayLanguage=sv&language=sv&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=266&dir=DESC", "status": 200, "scope": "NordicMainMarkets", "language": "sv", "start": 266, "pagination": "row-offset", "query_text": "Vicore Pharma Holding", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 0, "new_rows": 0, "total_count": null, "from_cache": false, "body_sha256": "507712be63f9ff0b9a9eb1fa3685a5d2ef954b9678fc29e19107a11a6ba4f129" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=Vicore+Pharma+Holding&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicFirstNorth&displayLanguage=sv&language=sv&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=0&dir=DESC", "status": 200, "scope": "NordicFirstNorth", "language": "sv", "start": 0, "pagination": "row-offset", "query_text": "Vicore Pharma Holding", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 4, "new_rows": 4, "total_count": null, "from_cache": false, "body_sha256": "8e2d7f05459cc103f8510333df870b328dd02ce1da39b2a73e9edd2e59f61bcb" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=Vicore+Pharma+Holding&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicFirstNorth&displayLanguage=sv&language=sv&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=4&dir=DESC", "status": 200, "scope": "NordicFirstNorth", "language": "sv", "start": 4, "pagination": "row-offset", "query_text": "Vicore Pharma Holding", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 0, "new_rows": 0, "total_count": null, "from_cache": false, "body_sha256": "e27b60cb74ad0e336cee9c3aa3436314395a27959baa132e37b1113a29192eb8" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=Vicore+Pharma+Holding&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicMainMarkets&displayLanguage=en&language=en&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=0&dir=DESC", "status": 200, "scope": "NordicMainMarkets", "language": "en", "start": 0, "pagination": "row-offset", "query_text": "Vicore Pharma Holding", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 100, "new_rows": 100, "total_count": null, "from_cache": false, "body_sha256": "85789920b46eec6a766ebe504020a694b4634a1420e31f0d3652aacf0b15f5e7" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=Vicore+Pharma+Holding&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicMainMarkets&displayLanguage=en&language=en&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=100&dir=DESC", "status": 200, "scope": "NordicMainMarkets", "language": "en", "start": 100, "pagination": "row-offset", "query_text": "Vicore Pharma Holding", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 100, "new_rows": 100, "total_count": null, "from_cache": false, "body_sha256": "52f49849cedfbb075c046aa9e53ed84fb8478e52c27e5d42966d89f00488817e" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=Vicore+Pharma+Holding&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicMainMarkets&displayLanguage=en&language=en&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=200&dir=DESC", "status": 200, "scope": "NordicMainMarkets", "language": "en", "start": 200, "pagination": "row-offset", "query_text": "Vicore Pharma Holding", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 46, "new_rows": 46, "total_count": null, "from_cache": false, "body_sha256": "d0e1169418b794b57d921920bf3452a74a8d8851f13d72a6b133e875d4302109" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=Vicore+Pharma+Holding&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicMainMarkets&displayLanguage=en&language=en&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=246&dir=DESC", "status": 200, "scope": "NordicMainMarkets", "language": "en", "start": 246, "pagination": "row-offset", "query_text": "Vicore Pharma Holding", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 0, "new_rows": 0, "total_count": null, "from_cache": false, "body_sha256": "5c9ae7ea3b6be02b6477658f3a7ce5885f8e7d2e012fb96534eed1a2fc954161" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=Vicore+Pharma+Holding&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicFirstNorth&displayLanguage=en&language=en&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=0&dir=DESC", "status": 200, "scope": "NordicFirstNorth", "language": "en", "start": 0, "pagination": "row-offset", "query_text": "Vicore Pharma Holding", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 2, "new_rows": 2, "total_count": null, "from_cache": false, "body_sha256": "a5407667c7c17ef8de65e99fd0be0a4075b19f2d8f99636dfa5cf4ff0f6d6e68" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=Vicore+Pharma+Holding&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicFirstNorth&displayLanguage=en&language=en&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=2&dir=DESC", "status": 200, "scope": "NordicFirstNorth", "language": "en", "start": 2, "pagination": "row-offset", "query_text": "Vicore Pharma Holding", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 0, "new_rows": 0, "total_count": null, "from_cache": false, "body_sha256": "8cf81a327a3a8b325adfd784ef5b23173c052fd172113cb13a000ad4e443c411" } ], "identity": { "slug": "vico", "instrument_id": "TX1937060", "resolved_url": "https://www.nasdaq.com/european-market-activity/shares/vico?id=TX1937060" }, "transport": "ordinary-http", "browser_used": false, "query_text": "Vicore Pharma Holding", "retrieved_at": "2026-08-04T19:47:09Z" }